

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康集團

Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Uni-Bio Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the latest unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 (the “**Period**”), the Group is expected to record a profit attributable to the owners of the parent of not less than HK\$60 million (2023: profit of HK\$39.4 million) for the Period.

Based on the information available to the Board, the Board considers such expected increase was mainly attributable to the sales revenue for the interim period of 2024 will increase by no less than 8% compared to that of HK\$249.9 million for the interim period of 2023, which was mainly attributable to the newly-launched product, Bogutai[®]; in terms of costs, we will effectively control the increase in marketing expenses, continue to deepen the cooperation with suppliers of raw materials, and lower the procurement cost of raw materials.

As the Company is still in the process of finalising the results for the six months ended 30 June 2024, the information contained in this announcement is based on the management’s preliminary review on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 and current information available to the Board and has not been reviewed by the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2024 which is expected to be published by the end of August 2024.

* For identification purpose only

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 9 August 2024

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.